Clearbridge Investments LLC Lowers Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Clearbridge Investments LLC reduced its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 241,029 shares of the company’s stock after selling 4,926 shares during the period. Clearbridge Investments LLC’s holdings in Prestige Consumer Healthcare were worth $16,595,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Opal Wealth Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare in the second quarter worth $26,000. Quest Partners LLC boosted its holdings in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the period. EverSource Wealth Advisors LLC grew its stake in Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares in the last quarter. Gladius Capital Management LP purchased a new stake in Prestige Consumer Healthcare during the 2nd quarter worth about $35,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Trading Up 0.7 %

NYSE:PBH opened at $68.83 on Friday. Prestige Consumer Healthcare Inc. has a 1 year low of $56.61 and a 1 year high of $75.80. The stock has a market cap of $3.42 billion, a P/E ratio of 16.51, a P/E/G ratio of 2.01 and a beta of 0.47. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23. The stock has a 50-day simple moving average of $71.13 and a 200-day simple moving average of $69.48.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The firm had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. During the same period in the prior year, the company posted $1.06 earnings per share. The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

PBH has been the subject of several recent research reports. DA Davidson lifted their price objective on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $94.20.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.